Eugene T. Perez

Partner

1-703-205-8000

Eugene Perez has practiced in the intellectual property field since 2000, and has extensive experience advising clients regarding management of their worldwide patent portfolios including preparation and prosecution of patent applications.  He specializes in the fields of chemistry (organic and inorganic, such as resins & polymers, materials science, rubbers), biotechnology (therapeutic methods, pharmaceutical chemistry, medical supplies, biomarkers and antibodies), and mechanical patents. His prosecution of Paris convention, PCT national phase, and foreign applications includes corresponding with clients and preparing replies to all USPTO correspondence such as Office Actions and Restriction Requirements, interviews with patent examiners, ex parte appeals, reissue applications, ex parte reexamination proceedings, inter partes reviews, conducting legal research, and preparing freedom-to-operate, patentability, infringement and validity opinion letters. Mr. Perez has also argued before the Court of Appeals for the Federal Circuit, as well as before the USPTO Patent Trial and Appeal Board.

Mr. Perez serves as the editor for BSKB’s Post Grant Proceedings website, a site devoted to post-grant patent review procedures, including IPR, post-grant reviews, patent reexamination and reissue.

Mr. Perez was recently included in the 2024 edition of The Best Lawyers in America® in the field of Patent Law. View Mr. Perez's profile here.

Services

Industries

Representative Matters

  • Inter partes reexamination control no. 95/000,138 (Fidia Farmaceutici S.p.A. v. Chemi S.p.A.) (USPN 6,645,742)
  • Inter partes reexamination control no. 95/000,153 (Galderma R&D v. Leo Pharmaceutical Products, Ltd.) (USPN 6,753,013)
  • Chemi S.p.A. v. Fidia Farmaceutici p.A., Appeal No. 2010-1514 (Fed. Cir.) (June 8, 2011) (argued) (on brief)
  • Leo Pharmaceutical Products, Ltd. v. Rea, Appeal No. 12-1520 (Fed. Cir.) (Aug. 12, 2013) (on brief)
  • Biomarin Pharmaceutical, Inc. v. Genzyme Therapeutic Products, Ltd., IPR2013-00534, IPR2013-00537
  • Biomarin Pharmaceutical, Inc. v. Duke University, IPR2013-00535
  • Genzyme Therapeutic Products, Ltd. v. Biomarin Pharmaceutical, Inc., Appeal No. 2015-1720, 2015-1721 (Fed. Cir.) (on brief)
  • Samsung Electronics Co., Ltd v. Ibex PT Holdings Co., Ltd., IPR2017-00101, IPR2017-00102
  • Celanese Int’l Corp. v. Daicel Corp., IPR2017-00162, IPR2017-00163, IPR2017-00164, IPR2017-00165, IPR2017-00166
  • Duke University v. Biomarin Pharmaceutical, Inc., Appeal No. 2016-1106 (Fed. Cir.) (on brief)
  • Samsung Electronics Co., Ltd v. Ibex PT Holdings Co., Ltd., IPR2018-00011, IPR2018-00012, IPR2018-00092, IPR2018-00093 (PTAB) (Decisions Denying Patent Owner Request for Rehearing, Aug. 27, 2020)
  • Duke University v. Biomarin Pharmaceutical, Inc., Appeal No. 2018-1696 (Fed. Cir.) (Oct. 11, 2019) (on brief)
  • Daicel Corp. Celanese Int’l Corp., Appeal No. 18-2130 (Fed. Cir.) (Nov. 5, 2019) (on brief)
  • Daicel Corp. Celanese Int’l Corp., Appeal No. 18-2131 (Fed. Cir.) (Nov. 5, 2019) (argued) (on brief) (awaiting PTAB Decision)
  • Samsung Electronics Co., Ltd v. Infobridge PTE. Ltd., IPR2017-00099, IPR2017-00100 (on remand)
  • Ex Parte Bayer Cropscience NV and Biogen IDEC MA, Inc., Reexamination Control Nos. 90/013,394; 90/013,449; 90/013,452; 90/013,453; 90/013,515; 90/013,563 (PTAB) (Examiner’s rejections reversed on appeal, Sept. 30, 2020)
  • Samsung Electronics Co., Ltd v. Ibex PT Holdings Co., Ltd., Appeal Nos. 2019-2034, 2019-2098, 2019-2136 (Fed. Cir.) (for IPR2018-00012, IPR2018-00094, IPR2018-00095) (Motions to dismiss filed by Samsung on Nov. 12, 2020)
  • Metrasens, Inc. et al. v. Kopp, IPR2022-01224

Speaking Engagements

    Current Speaking Engagements

Articles

Presentations